| Abstract: |
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital. |
| Inventor: |
WHALLEY, Ben (Reading, GB); WILLIAMS, Claire (Reading, GB); STEPHENS, Gary (Reading, GB); FUTAMURA, Takashi (Osaka, JP) |
| Applicant: |
GW Pharma Limited (Salisbury, GB); Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) |
| Face Assignee: |
N/A |
| Filed: |
2020-09-04 |
| Issued: |
2021-04-08 |
| Claims: |
7 |
|
US20210100755
|
22. A method for the treatment of epileptic seizures, which comprises administering to a subject in need thereof a therapeutically effective amount of a cannabis plant extract comprising a phytocannabinoid containing component and a non-phytocannabinoid containing component, wherein the phytocannabinoid containing component comprises at least 50% (w/w) of the cannabis plant extract and contains as a principal phytocannabinoid, CBDV, and as a secondary phytocannabinoid, CBD, and wherein the non-phytocannabinoid containing component comprises a monoterpene fraction and a sesquiterpene fraction.
(2)
(0)
|
|
